In Brief: Pacific Biometrics, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Pacific Biometrics, Inc.: Completes pilot clinical studies on its non-invasive Osteopatch used in the diagnosis of osteoporotic disease. The patch is affixed to the patient's skin to collect sweat samples, which are used in "the dectection of biochemical markers of bone loss," the Irvine, California firm says. Pacific Biometrics has signed up several U.S. medical centers as sites for its upcoming clinical trials, which are expected to include 300 subjects. The company plans to submit a 510(k) once the studies are completed...
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.